{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:35:16Z","timestamp":1793090116531,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["AIRC grant MFAG 2020 ID 24698"],"award-info":[{"award-number":["AIRC grant MFAG 2020 ID 24698"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP E53D23012810001"],"award-info":[{"award-number":["CUP E53D23012810001"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP E93C22001860006"],"award-info":[{"award-number":["CUP E93C22001860006"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR - M4C2-I1.3 Project PE_00000019 \\\"HEAL ITALIA\\\""],"award-info":[{"award-number":["PNRR - M4C2-I1.3 Project PE_00000019 \\\"HEAL ITALIA\\\""]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"MIUR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010824","name":"Angela Serra Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019771","name":"European Union's Research and Innovation","doi-asserted-by":"publisher","award":["CUP E93C22001860006"],"award-info":[{"award-number":["CUP E93C22001860006"]}],"id":[{"id":"10.13039\/100019771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019771","name":"European Union's Research and Innovation","doi-asserted-by":"publisher","award":["CUP E53D23012810001"],"award-info":[{"award-number":["CUP E53D23012810001"]}],"id":[{"id":"10.13039\/100019771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105633","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:16:49Z","timestamp":1790723809000},"page":"105633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical implications of the type and genomic location of pathogenic BRCA1 and BRCA2 variants in hereditary breast and ovarian cancer"],"prefix":"10.1016","volume":"227","author":[{"given":"Emma","family":"Zattarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Piombino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tenedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1858-8058","authenticated-orcid":false,"given":"Flavia","family":"Siciliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Galasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Grippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Mand\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-5296","authenticated-orcid":false,"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Blondeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Tagliafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3567-3278","authenticated-orcid":false,"given":"Giovanni","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Toss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105633_bib1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.annonc.2025.04.010","article-title":"Association of gene variant type and location with breast cancer risk in the general population","volume":"36","author":"Akamandisa","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-13508-3","article-title":"Understanding and predicting the functional consequences of missense mutations in BRCA1 and BRCA2","volume":"12","author":"Aljarf","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105633_bib3","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation\u2013positive women with ovarian cancer: a report from the Australian ovarian cancer study group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/tbj.12392","article-title":"Genotype-Phenotype correlations by ethnicity and mutation location in BRCA mutation carriers","volume":"21","author":"Bayraktar","year":"2015","journal-title":"Breast J."},{"key":"10.1016\/j.critrevonc.2026.105633_bib5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105633_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.6744","article-title":"Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes","volume":"8","author":"Breast Cancer Association Consortium","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105633_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105633_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-022-06776-0","article-title":"Prognostic impact of germline BRCA1\/2 pathogenic variants in breast cancer","volume":"197","author":"Corso","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105633_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000479155","article-title":"Evaluation of Transvaginal Ultrasound plus CA-125 measurement and prophylactic salpingo-oophorectomy in women at different risk levels of ovarian cancer: the modena study group cohort study","volume":"93","author":"Cortesi","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2026.105633_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/annonc\/mdt422","article-title":"A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1\/2-positive Italian women","volume":"25","author":"Cortesi","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Daly","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"10.1016\/j.critrevonc.2026.105633_bib13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nsmb.3236","article-title":"Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection","volume":"23","author":"Densham","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib14","doi-asserted-by":"crossref","first-page":"43653","DOI":"10.18632\/oncotarget.17613","article-title":"Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting","volume":"8","author":"Dougherty","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105633_bib15","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1172\/JCI70196","article-title":"BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1","volume":"126","author":"Drost","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2026.105633_bib16","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9873954","article-title":"Cancer surveillance in healthy carriers of germline pathogenic variants in BRCA1\/2: A review of secondary prevention guidelines","volume":"2020","author":"Dullens","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib17","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1073\/pnas.0610887104","article-title":"Estrogen receptor \u03b1 is a putative substrate for the BRCA1 ubiquitin ligase","volume":"104","author":"Eakin","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105633_bib18","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-16-0297","article-title":"BRCA2 functions: from DNA repair to replication fork stabilization","volume":"23","author":"Fradet-Turcotte","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105633_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.813457","article-title":"BRCA1 and breast cancer: molecular mechanisms and therapeutic strategies","volume":"10","author":"Fu","year":"2022","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113144","article-title":"Replication stress and defective checkpoints make fallopian tube epithelial cells putative drivers of high-grade serous ovarian cancer","volume":"42","author":"Galhenage","year":"2023","journal-title":"Cell. Rep."},{"key":"10.1016\/j.critrevonc.2026.105633_bib21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tranon.2019.11.003","article-title":"Clinical Evaluation of BRCA1\/2 mutation in mexican ovarian cancer patients","volume":"13","author":"Gallardo-Rinc\u00f3n","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ng0197-103","article-title":"Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene","volume":"15","author":"Gayther","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2026.105633_bib23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/ng1295-428","article-title":"Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation","volume":"11","author":"Gayther","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2026.105633_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105633_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/GME.0000000000001883","article-title":"The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance","volume":"29","author":"Grandi","year":"2021","journal-title":"Menopause"},{"key":"10.1016\/j.critrevonc.2026.105633_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/13625187.2019.1647335","article-title":"Combined hormonal contraceptives in BRCA gene mutation carriers: why not?","volume":"24","author":"Grandi","year":"2019","journal-title":"Eur. J. Contracept. Reprod. Health Care."},{"key":"10.1016\/j.critrevonc.2026.105633_bib27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ygyno.2021.12.013","article-title":"Clinical outcomes of BRCA1\/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer","volume":"164","author":"Ha","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-022-03978-6","article-title":"Copy number variants as modifiers of breast cancer risk for BRCA1\/BRCA2 pathogenic variant carriers","volume":"5","author":"Hakkaart","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib29","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03716-8","article-title":"Mechanisms of BRCA1-BARD1 nucleosome recognition and ubiquitylation","volume":"596","author":"Hu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105633_bib30","article-title":"Functional evaluation and clinical classification of BRCA2 variants","author":"Huang","year":"2025","journal-title":"Nature 110"},{"key":"10.1016\/j.critrevonc.2026.105633_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920975326","article-title":"BRCA1\/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients","volume":"12","author":"Incorvaia","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/ph17030333","article-title":"BRCA1 and its vulnerable C-Terminal BRCT domain: structure, function, genetic mutations and links to diagnosis and treatment of breast and ovarian cancer","volume":"17","author":"Ismail","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.critrevonc.2026.105633_bib33","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/cancers17050756","article-title":"The Association Between Location of BRCA Mutation and Efficacy of PARP Inhibitor as a Frontline Maintenance Therapy in Advanced Epithelial Ovarian Cancer","volume":"17","author":"Kim","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105633_bib34","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3390\/cancers17101661","article-title":"Survival Outcomes Associated with the Location of BRCA mutations in ovarian cancer: a systematic review and meta-analysis","volume":"17","author":"Kim","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105633_bib35","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105633_bib36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/1078-0432.CCR-17-2136","article-title":"Location of Mutation in BRCA2 gene and survival in patients with ovarian cancer","volume":"24","author":"Labidi-Galy","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105633_bib37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.annonc.2022.11.003","article-title":"Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1\/ENGOT-ov25 trial subgroup exploratory analysis","volume":"34","author":"Labidi-Galy","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib38","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO-24-01334","article-title":"Clinical behavior of breast cancer in young BRCA carriers and prediagnostic awareness of germline BRCA Status","volume":"43","author":"Lambertini","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5483\/BMBRep.2017.50.4.015","article-title":"Nonsense-mediated mRNA decay at the crossroads of many cellular pathways","volume":"50","author":"Lejeune","year":"2017","journal-title":"BMB Rep."},{"key":"10.1016\/j.critrevonc.2026.105633_bib40","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.gim.2022.08.005","article-title":"Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants","volume":"24","author":"Li","year":"2022","journal-title":"Genet. Med."},{"key":"10.1016\/j.critrevonc.2026.105633_bib41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105633_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.106060","article-title":"A novel BRCA mutation classification system reveals differential responses to PARP inhibition and prognostic outcomes in epithelial ovarian cancer: a multicenter study","volume":"11","author":"Liu","year":"2026","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105633_bib43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/ijgc-2022-003893","article-title":"Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients","volume":"33","author":"Marchetti","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105633_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105299","article-title":"Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1\/2 mutation type and site: a multicenter real-world study","volume":"10","author":"Marchetti","year":"2025","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105633_bib45","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3390\/genes14030684","article-title":"Personalized systemic therapies in hereditary cancer syndromes","volume":"14","author":"Mastrodomenico","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.critrevonc.2026.105633_bib46","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1200\/JCO.2016.67.0554","article-title":"Population Frequency of Germline BRCA1\/2 Mutations","volume":"34","author":"Maxwell","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","article-title":"BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","volume":"8","author":"Maxwell","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105633_bib48","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s41436-020-0814-5","article-title":"Alternative mRNA splicing can attenuate the pathogenicity of presumed loss-of-function variants in BRCA2","volume":"22","author":"Mesman","year":"2020","journal-title":"Genet. Med."},{"key":"10.1016\/j.critrevonc.2026.105633_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2026.104679","article-title":"Decoding BRCA1 and BRCA2 mutations in high-grade serous ovarian cancer: impact of location and type of mutation on prognosis and PARP Inhibitor Treatment","volume":"36","author":"Momi","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105633_bib50","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105633_bib51","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41586-022-04558-8","article-title":"A joint NCBI and EMBL-EBI transcript set for clinical genomics and research","volume":"604","author":"Morales","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105633_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-20500-4","article-title":"Assessment of small in-frame indels and C-terminal nonsense variants of BRCA1 using a validated functional assay","volume":"12","author":"Nepomuceno","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105633_bib53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41698-024-00741-4","article-title":"Reduced penetrance BRCA1 and BRCA2 pathogenic variants in clinical germline genetic testing","volume":"8","author":"Pal","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib54","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","article-title":"Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel","volume":"111","author":"Parsons","year":"2024","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.critrevonc.2026.105633_bib55","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.3390\/cancers14112804","article-title":"Insights into the possible molecular mechanisms of resistance to PARP Inhibitors","volume":"14","author":"Piombino","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105633_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6384190","article-title":"Secondary prevention in hereditary breast and\/or ovarian cancer syndromes other Than BRCA","volume":"2020","author":"Piombino","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.634217","article-title":"Germline structural variations in cancer predisposition genes","volume":"12","author":"P\u00f3cza","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.critrevonc.2026.105633_bib58","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105633_bib59","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105633_bib60","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105633_bib61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105633_bib62","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41523-021-00361-2","article-title":"Value of the loss of heterozygosity to BRCA1 variant classification","volume":"8","author":"Santana Dos Santos","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105633_bib63","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e46","article-title":"Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy","volume":"33","author":"Sekine","year":"2022","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib65","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12032-018-1085-8","article-title":"A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors","volume":"35","author":"Shailani","year":"2018","journal-title":"Med. Oncol. North. Lond. Engl."},{"key":"10.1016\/j.critrevonc.2026.105633_bib66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2024.08.012","article-title":"Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report","volume":"190","author":"\u0160kof","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib67","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2021.08.030","article-title":"Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer","volume":"163","author":"Swisher","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib68","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.annonc.2020.10.470","article-title":"A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance","volume":"32","author":"Tobalina","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib69","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.annonc.2025.11.004","article-title":"Association between type and location of germline BRCA1\/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study","volume":"37","author":"Toss","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib70","doi-asserted-by":"crossref","first-page":"301","DOI":"10.23736\/S0026-4806.19.06091-9","article-title":"Hereditary ovarian cancers: state of the art","volume":"110","author":"Toss","year":"2019","journal-title":"Minerva Med."},{"key":"10.1016\/j.critrevonc.2026.105633_bib71","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1158\/2767-9764.CRC-21-0099","article-title":"Influence of germline BRCA genotype on the survival of patients with triple-negative breast cancer","volume":"1","author":"Villarreal-Garza","year":"2021","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.critrevonc.2026.105633_bib72","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.onc.1209033","article-title":"Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene?","volume":"25","author":"Ware","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105633_bib73","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105633_bib74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41523-025-00859-z","article-title":"Real-world effectiveness of PARP inhibitors after CDK4\/6 inhibitor therapy in BRCA-mutated HR-positive\/HER2-negative advanced breast cancer","volume":"11","author":"Zattarin","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105633_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104109","article-title":"Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: Different biological and clinical entities with potentially diverse therapeutic opportunities","volume":"190","author":"Zattarin","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105633_bib76","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1038\/s41467-026-71134-3","article-title":"Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma","volume":"17","author":"Zwimpfer","year":"2026","journal-title":"Nat. Commun."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:49:58Z","timestamp":1793087398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":76,"alternative-id":["S1040842826005202"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105633","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implications of the type and genomic location of pathogenic BRCA1 and BRCA2 variants in hereditary breast and ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105633"}}